Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial – JOURNAL OF THORACIC ONCOLOGY

by | Jan 1, 2024 | Publicaciones - B-22 | 0 comments

Reck, M; Barlesi, F; Yang, JCH; Westeel, V; Felip, E; Özgüroglu, M; Dols, MC; Sullivan, R; Kowalski, DM; Andric, Z; Lee, DH; Sezer, A; Hu, P; Wang, XZ; von Heydebreck, A; Jacob, N; Mehr, KT; Park, K – 2024 – 10.1016/j.jtho.2023.09.1445